This week, the overall grades of nine Pharmaceutical stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
Corcept Therapeutics’ (NASDAQ:CORT) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, CORT also gets F’s. To get an in-depth look at CORT, get Portfolio Grader’s complete analysis of CORT stock.
Cornerstone Therapeutics’ (NASDAQ:CRTX) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Cornerstone Therapeutics is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products mainly for the respiratory and related markets. The stock gets F’s in Earnings Surprise and Margin Growth. The stock price has dropped 9.9% over the past month, worse than the 4.2% increase the Nasdaq has seen over the same period of time. For a full analysis of CRTX stock, visit Portfolio Grader.
Bristol-Myers Squibb (NYSE:BMY) gets weaker ratings this week as last week’s C drops to a D. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. The stock gets F’s in Earnings Growth, Earnings Momentum, and Sales Growth. The stock’s trailing PE Ratio is 29.90. For more information, get Portfolio Grader’s complete analysis of BMY stock.
ViroPharma (NASDAQ:VPHM) earns a D this week, moving down from last week’s grade of C. ViroPharma develops and commercializes products that address serious diseases, with a focus on those used by physician specialists or in hospital settings. The stock receives F’s in Earnings Growth, Earnings Momentum, Earnings Revisions, and Sales Growth. As of Dec. 21, 2012, 11.5% of outstanding ViroPharma shares were held short. The stock currently has a trailing PE Ratio of 30.00. To get an in-depth look at VPHM, get Portfolio Grader’s complete analysis of VPHM stock.
MAP Pharmaceuticals (NASDAQ:MAPP) experiences a ratings drop this week, going from last week’s C to a D. MAP Pharmaceuticals develops treatments for respiratory and CNS diseases. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. As of Dec. 21, 2012, 16.8% of outstanding MAP Pharmaceuticals shares were held short. For more information, get Portfolio Grader’s complete analysis of MAPP stock.
This week, Hi-Tech Pharmacal (NASDAQ:HITK) drops from C to a D rating. Hi-Tech Pharmacal manufactures prescription and over-the-counter generic and branded pharmaceuticals in liquid and semi-solid dosage forms. For a full analysis of HITK stock, visit Portfolio Grader.
This is a rough week for GlaxoSmithKline (NYSE:GSK). The company’s rating falls to D from the previous week’s C. GlaxoSmithKline is a research-based pharmaceutical company. The stock also gets an F in Earnings Momentum. For more information, get Portfolio Grader’s complete analysis of GSK stock.
The rating of Hospira (NYSE:HSP) declines this week from C to a D. Hospira is a global pharmaceutical and medication delivery company that develops, manufactures and markets products. The stock also rates an F in Margin Growth. To get an in-depth look at HSP, get Portfolio Grader’s complete analysis of HSP stock.
Teva Pharmaceutical Industries (NYSE:TEVA) earns a D this week, falling from last week’s grade of C. Teva Pharmaceutical is a global company that develops, produces and markets generic drugs covering all major treatment categories. The stock also gets an F in Earnings Growth. For a full analysis of TEVA stock, visit Portfolio Grader.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
